VEGFA and non-small cell lung carcinoma: Evidence has also suggested that anti-PD-1 and anti-vascular endothelial growth factor (VEGF) combined therapy may be a more favorable treatment option than any single reagent for NSCLC patients who had failed on the first-line or later treatment, and this therapeutic response was not affected by VEGF mutational status (15–17).